Investigating Usability of c-SIGHT in the Homes of Brain Injury Survivors (c-SIGHT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03963661 |
Recruitment Status :
Recruiting
First Posted : May 28, 2019
Last Update Posted : August 12, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Stroke Brain Injuries Spatial Neglect Attention Deficit | Behavioral: c-SIGHT (computorized spatial innatention grasping home-based therapy) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 10 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Investigating a Portable Patient-led Virtual Reality Platform for Assessment and Rehabilitation of Hemispatial Neglect: a Usability Study |
Actual Study Start Date : | May 6, 2019 |
Estimated Primary Completion Date : | February 1, 2020 |
Estimated Study Completion Date : | April 3, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: c-SIGHT
SIGHT requires participants to grasp and lift rods with their less impaired arm.
|
Behavioral: c-SIGHT (computorized spatial innatention grasping home-based therapy)
C-SIGHT will be self-administered at people's homes. c-SIGHT is a computerized therapy administered via people's television. The therapy involves performing repeated rod lifts with the less impaired arm in response to auditory and visual instructions presented on the television screen connected to a laptop. A small motion-tracking camera monitors rod lifts during therapy sessions. People will be asked to self-administer c-SIGHT for 1 hour a day (30min after breakfast and 30min after lunch) for 7 consecutive days. The first day of therapy will be performed with a therapist there for training purposes.
Other Name: visuomotor feedback training |
- Behavioral Inattention Test (BIT) conventional sub tests [ Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2) ]Standardized measure of spatial inattention
- Line bisection Test [ Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2) ]Test for spatial inattention which measures spatial biases when marking middle of 10 20mm lines. Bisection error bigger that 6mm is considered evidence of spatial inattention.
- Broken Hearts test from Oxford Cognitive Screening (paper version) [ Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2) ]Standardized measure of spatial inattention
- Computerized extrapersonal neglect test (CENT) [ Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2) ]Computerized test measuring ego and allocentric neglect sub types in extra personal space via television screen
- Catherine Bergego Scale [ Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2) ]
Standardized checklist to detect presence and degree of unilateral neglect during observation of everyday life situations. The scale also measures self-awareness of behavioral neglect (anosognosia).
The CBS uses a 4-point rating scale to indicate the severity of neglect for each item:
0 = no neglect
- = mild neglect (patient always explores the right hemispace first and slowly or hesitantly explores the left side)
- = moderate neglect (patient demonstrates constant and clear left-sided omissions or collisions)
- = severe neglect (patient is only able to explore the right hemispace)
This results in a total score out of 30.
Azouvi et al. (2002, 2003) have reported arbitrary ratings of neglect severity according to total scores:
0 = No behavioral neglect 1-10 = Mild behavioral neglect 11-20 = Moderate behavioral neglect 21-30 = Severe behavioral neglect
- Pinch and grip force task (dynamometer) [ Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2) ]Measures upper limb function
- Caregiver Burden Scale [ Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2) ]
To assess perceived burden among people caring for others with disabilities. There are 22 items in which the carer rates perceived burden from 0 (never) to 4 (nearly always).
A total score of 0 to 20 = little or no burden; 21 to 40 = mild to moderate burden; 41 to 60 = moderate to severe burden; 61 to 88 = severe burden.
- Stroke Specific Quality of Life Scale (SS-QOL) [ Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2) ]A patient-centered outcome measure intended to provide an assessment of health-related quality of life (HRQOL) specific to patients with stroke. Patients must respond to each question of the SS-QOL with reference to the past week. It is a self-report scale containing 49 items in 12 domains. Items are rated on a 5-point Likert scale. Higher scores indicate better functioning. The SS-QOL yields both domain scores and an overall SS-QOL summary score. The domain scores are unweighted averages of the associated items while the summary score is an unweighted average of all twelve domain scores.
- System Usability Scale [ Time Frame: immediately after 7 days of therapy (T2) ]
To assess usability of devices and applications. Participants are asked to score the following 10 items with one of five responses that range from Strongly Agree to Strongly disagree. The participant's scores for each question are converted to a new number, added together and then multiplied by 2.5 to convert the original scores of 0-40 to 0-100. Though the scores are 0-100, these are not percentages and should be considered only in terms of their percentile ranking.
Based on research, a SUS score above a 68 would be considered above average and anything below 68 is below average.
- Semi-structured interview at end of study with carer and stroke survivor [ Time Frame: immediately after 7 days of therapy (T2) ]To assess usability (qualitative data)
- WAIS Digit span (control measure) [ Time Frame: Change from baseline (T0) to 7 days (pre-treatment baseline, T1) and from T1 to immediately after 7 days of therapy (T2) ]Digit span from WAIS (forward, backward and sequential) is used as a control task

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- +18
- suffered brain injury
- have TV with around 2 meters in front of it to be able to run the therapy
- live in the Norfolk, Suffolk, Essex or Cambridgeshire (UK)
- no other pre-existing neurological disorders (such as dementia)
- no language impairment (able to follow 1-stage command)
- mental capacity to consent
- no known learning disability
- no major psychiatric illness
- no history of substance abuse

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03963661
Contact: Stephanie Rossit, Ph.D | +44 (0)160359 1674 | s.rossit@uea.ac.uk | |
Contact: Valerie Pomeroy, Ph.D | +44 (0)1603 59 1668 | v.pomeroy@uea.ac.uk |
United Kingdom | |
University of East Anglia | Recruiting |
Norwich, Norfolk, United Kingdom, NR4 7TJ | |
Contact: Stephanie Rossit, PhD | |
Principal Investigator: Stephanie Rossit | |
Sub-Investigator: Valerie Pomeroy | |
Sub-Investigator: Amy Jolly | |
Sub-Investigator: Helen Morse |
Publications:
Responsible Party: | Stephanie Rossit, Principal Investigator, University of East Anglia |
ClinicalTrials.gov Identifier: | NCT03963661 |
Other Study ID Numbers: |
R206721 |
First Posted: | May 28, 2019 Key Record Dates |
Last Update Posted: | August 12, 2019 |
Last Verified: | August 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Telerehabilitation Spatial neglect SIGHT Computorized therapy |
Stroke Innatention Self-admnistered therapy Usability |
Brain Injuries Wounds and Injuries Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Craniocerebral Trauma Trauma, Nervous System |